Skip to main content
DNA
NYSE Life Sciences

Ginkgo 10-Q: Q3 Loss Narrows to $41M, $285M Liquidity Funds 12+ Months

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$12.3
Mkt Cap
$832.999M
52W Low
$5.37
52W High
$18.22
52W Position info
129% above low
Off High info
32% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

DNA has more than doubled off its 52-week low of $5.37.

Summary

Ginkgo's Q3 10-Q shows the net loss narrowing to $41.0M from $80.8M on cost cuts, with $285.4M of cash and securities the company says covers at least 12 months of operations.


Key Events · Earnings and Guidance · DNA

  • Q3 Loss Nearly Halved

    Net loss was $41.0M versus $80.8M a year ago, as R&D fell to $40.9M from $69.4M and G&A to $28.6M from $37.0M.

  • Liquidity Covers 12 Months

    Cash and cash equivalents of $84.5M plus $200.9M of marketable securities total $285.4M, which management says funds projected operations through at least the next 12 months.

  • Restricted Balances Jump

    Restricted cash and marketable securities, non-current rose to $84.2M from $38.1M at December 31, 2025, shrinking the truly liquid pool.

  • ATM Drip Continues

    2.7M Class A shares were sold for $23.0M net in the first nine months; $41.1M of net proceeds has been raised since the $100.0M Sales Agreement began.


Analysis · DNA · Life Sciences

The headline numbers were already out on November 5, but the 10-Q is where the balance sheet gets audited-level scrutiny. Cash and cash equivalents fell to $84.5M from $167.2M at year-end, yet total liquidity of $285.4M (including $200.9M of marketable securities) is stated to fund operations through at least the next 12 months — that removes near-term financing risk even as the company keeps leaning on its ATM. The offset is that $84.2M of restricted cash and securities now sits outside that liquid pool, up from $38.1M, and the company still burned $117.0M of operating cash in nine months. Cost cuts are real: R&D fell to $40.9M from $69.4M and G&A to $28.6M from $37.0M, which is why the quarterly loss nearly halved.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DNA was trading at $12.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $833M. The 52-week trading range was $5.37 to $18.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DNA - Latest Insights

DNA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $12.44 info
Change: +$2.65 (+27%) info
Market Cap: $832.999M info
DNA
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $9.95
Real-time Price: $12.44 info
Change: +$2.50 (+25%) info
Market Cap: $832.999M info
DNA
Aug 06, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $12.44 info
Change: +$3.94 (+46%) info
Market Cap: $832.999M info
DNA
May 07, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.05
Real-time Price: $12.44 info
Change: +$3.39 (+38%) info
Market Cap: $832.999M info
DNA
May 07, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.56
Real-time Price: $12.44 info
Change: +$3.88 (+45%) info
Market Cap: $832.999M info